27 results on '"O'Brien, Susan"'
Search Results
2. Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial
3. Modest activity of pomalidomide in patients with myelofibrosis and significant anemia
4. Ubiquitin–proteasome system profiling in acute leukemias and its clinical relevance
5. Circulating Ki-67 index in plasma as a biomarker and prognostic indicator in chronic lymphocytic leukemia
6. Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse
7. Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL
8. Circulating Ki-67 protein in plasma as a biomarker and prognostic indicator of acute lymphoblastic leukemia
9. Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia
10. An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation
11. T-cell large granular lymphocytic (T-LGL) leukemia: Experience in a single institution over 8 years
12. Clinical relevance of soluble HLA-I and β2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease
13. The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)
14. Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome
15. Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes
16. Alemtuzumab: validation of a sensitive and simple enzyme-linked immunosorbent assay
17. Telomerase activity is not a prognostic factor in chronic lymphocytic leukemia
18. Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin’s lymphoma or Hodgkin’s lymphoma
19. A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia
20. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase
21. CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia
22. Clinical relevance of Flt1 and Tie1 angiogenesis receptors expression in B-cell chronic lymphocytic leukemia (CLL)
23. Variations in the low levels of cyclin D1/BCL1 have prognostic value in chronic lymphocytic leukemia
24. The prognostic significance of 13q14 deletions in chronic lymphocytic leukemia
25. Elacytarabine, a novel 5′-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia
26. Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate
27. A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.